Compare Veritone Inc (VERI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Veritone Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Veritone Inc trades at $1.49 (market cap $138.04M), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 972.5× Veritone Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| VERI | VRTX | |
|---|---|---|
Market Cap | $138.04M | $134.25B |
Sector | Technology | Health |
52-Week High | $8.39 | $529.65 |
52-Week Low | $1.00 | $376.62 |
Enterprise Value | $170.07M | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
